A2A Pharmaceuticals, Inc. - Sep 17, 2021 Form 4 Insider Report for Biomea Fusion, Inc. (BMEA)

Role
10%+ Owner
Signature
/s/ Sotirios Stergiopoulos, CEO
Stock symbol
BMEA
Transactions as of
Sep 17, 2021
Transactions value $
$379,852
Form type
4
Date filed
9/21/2021, 04:05 PM
Next filing
Jun 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMEA Common Stock Purchase $380K +34.7K +0.79% $10.96 4.4M Sep 17, 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.89 to $11.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 These shares are held directly by A2A Pharmaceuticals Inc. Sotirios Stergiopoulos is a member of the Issuer's Board of Directors and is an affiliate of the Reporting Person.